168 related articles for article (PubMed ID: 9862327)
21. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis.
Ruderman EM; Pope RM
Arthritis Res Ther; 2005; 7 Suppl 2(Suppl 2):S21-5. PubMed ID: 15833145
[TBL] [Abstract][Full Text] [Related]
22. Evidence that induction of tolerance in vivo involves active signaling via a B7 ligand-dependent mechanism: CTLA4-Ig protects V beta 8+ T cells from tolerance induction by the superantigen staphylococcal enterotoxin B.
Lane P; Haller C; McConnell F
Eur J Immunol; 1996 Apr; 26(4):858-62. PubMed ID: 8625979
[TBL] [Abstract][Full Text] [Related]
23. CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: Comparison with blockade of interleukin-6.
Iwahashi C; Fujimoto M; Nomura S; Serada S; Nakai K; Ohguro N; Nishida K; Naka T
Exp Eye Res; 2015 Nov; 140():53-64. PubMed ID: 26297802
[TBL] [Abstract][Full Text] [Related]
24. T cells are the main cell type expressing B7-1 and B7-2 in the central nervous system during acute, relapsing and chronic experimental autoimmune encephalomyelitis.
Cross AH; Lyons JA; San M; Keeling RM; Ku G; Racke MK
Eur J Immunol; 1999 Oct; 29(10):3140-7. PubMed ID: 10540325
[TBL] [Abstract][Full Text] [Related]
25. Blockade of T cell costimulation by CTLA4-Ig inhibits lung inflammation in murine hypersensitivity pneumonitis.
Israël-Assayag E; Fournier M; Cormier Y
J Immunol; 1999 Dec; 163(12):6794-9. PubMed ID: 10586079
[TBL] [Abstract][Full Text] [Related]
26. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis.
Weinberg AD; Wegmann KW; Funatake C; Whitham RH
J Immunol; 1999 Feb; 162(3):1818-26. PubMed ID: 9973447
[TBL] [Abstract][Full Text] [Related]
27. Inhibition by CTLA4Ig of experimental allergic encephalomyelitis.
Arima T; Rehman A; Hickey WF; Flye MW
J Immunol; 1996 Jun; 156(12):4916-24. PubMed ID: 8648142
[TBL] [Abstract][Full Text] [Related]
28. [Costimulatory molecules in autoimmunity: role of CD28/CTLA4-CD80/CD86].
Nakajima A; Azuma M
Nihon Rinsho; 1997 Jun; 55(6):1419-24. PubMed ID: 9200926
[TBL] [Abstract][Full Text] [Related]
29. Local production of CTLA4-Ig by adenoviral-mediated gene transfer to the pancreas induces permanent allograft survival and donor-specific tolerance.
Liu C; Deng S; Yang Z; Kucher T; Guo F; Gelman A; Chen H; Naji A; Shaked A; Brayman KL
Transplant Proc; 1999; 31(1-2):625-6. PubMed ID: 10083267
[No Abstract] [Full Text] [Related]
30. A gene therapy or purified CTLA4IgG treatment of experimental allergic encephalomyelitis.
Kawaguchi Y
Hokkaido Igaku Zasshi; 1999 Nov; 74(6):467-75. PubMed ID: 10642893
[TBL] [Abstract][Full Text] [Related]
31. T cell proliferation-augmenting activities of the gene 3 protein derived from a phage library clone with CD80-binding activity.
Fukumoto T; Torigoe N; Ito Y; Kajiwara Y; Sugimura K
J Immunol; 1998 Dec; 161(12):6622-8. PubMed ID: 9862690
[TBL] [Abstract][Full Text] [Related]
32. Effect of adenovirus-mediated gene transfer with CTLA4-Ig gene in organ transplantation.
Hayashi S; Namii Y; Guan-Lin M; Dai-Kaku L; Kobayashi T; Nagasaka T; Yokoyama I; Hamada H; Takagi H
Transplant Proc; 1999 Aug; 31(5):1944-5. PubMed ID: 10455927
[No Abstract] [Full Text] [Related]
33. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation.
Cross AH; Girard TJ; Giacoletto KS; Evans RJ; Keeling RM; Lin RF; Trotter JL; Karr RW
J Clin Invest; 1995 Jun; 95(6):2783-9. PubMed ID: 7539461
[TBL] [Abstract][Full Text] [Related]
34. Differential requirements of naïve and memory T cells for CD28 costimulation in autoimmune pathogenesis.
Perrin PJ; Lovett-Racke A; Phillips SM; Racke MK
Histol Histopathol; 1999 Oct; 14(4):1269-76. PubMed ID: 10506942
[TBL] [Abstract][Full Text] [Related]
35. Acquired thymic tolerance: role of CTLA4 in the initiation and maintenance of tolerance in a clinically relevant autoimmune disease model.
Issazadeh S; Zhang M; Sayegh MH; Khoury SJ
J Immunol; 1999 Jan; 162(2):761-5. PubMed ID: 9916696
[TBL] [Abstract][Full Text] [Related]
36. Immunoinhibitory DNA vaccine protects against autoimmune diabetes through cDNA encoding a selective CTLA-4 (CD152) ligand.
Prud'homme GJ; Chang Y; Li X
Hum Gene Ther; 2002 Feb; 13(3):395-406. PubMed ID: 11860706
[TBL] [Abstract][Full Text] [Related]
37. B7-CD28/CTLA-4 costimulatory pathways are required for the development of T helper cell 2-mediated allergic airway responses to inhaled antigens.
Keane-Myers A; Gause WC; Linsley PS; Chen SJ; Wills-Karp M
J Immunol; 1997 Mar; 158(5):2042-9. PubMed ID: 9036947
[TBL] [Abstract][Full Text] [Related]
38. Co-injection of adenovirus expressing CTLA4-Ig prolongs adenovirally mediated lacZ reporter gene expression in the mouse retina.
Ali RR; Reichel MB; Byrnes AP; Stephens CJ; Thrasher AJ; Baker D; Hunt DM; Bhattacharya SS
Gene Ther; 1998 Nov; 5(11):1561-5. PubMed ID: 9930310
[TBL] [Abstract][Full Text] [Related]
39. Medullary thymic epithelium expresses a ligand for CTLA4 in situ and in vitro.
Nelson AJ; Hosier S; Brady W; Linsley PS; Farr AG
J Immunol; 1993 Sep; 151(5):2453-61. PubMed ID: 8395547
[TBL] [Abstract][Full Text] [Related]
40. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis.
Perrin PJ; Maldonado JH; Davis TA; June CH; Racke MK
J Immunol; 1996 Aug; 157(4):1333-6. PubMed ID: 8759711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
